Advertisement

Topics

National Emphysema/COPD Association Company Profile

07:15 EDT 23rd September 2017 | BioPortfolio


News Articles [2232 Associated News Articles listed on BioPortfolio]

COPD National Action Plan aims to reduce the burden of the third leading cause of death

First national framework designed to address key issues associated with COPD.

Sunovion Receives CRL for COPD Candidate SUN-101/eFlow

Sunovion Pharmaceuticals has acknowledged that its NDA for its chronic obstructive pulmonary disease (COPD) treatment candidate SUN-101/eFlow ® (glycopyrrolate) has been rejected by the FDA. ...

National Plan for COPD Care

The final version of a coordinated nationwide plan to address chronic obstructive pulmonary disease (COPD), the third leading cause of death in the United States, was unveiled last month by the Nation...

Exposure to Disinfectants Linked to COPD

There is an association between the regular use of cleaning products and the development of COPD, an analysis of data from the Nurses' Health Study II shows. Medscape Medical News

Sunovion receives complete response letter from FDA for SUN-101/eFlow for COPD

Sunovion Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) for SUN-101/eFlow (glycopyrrolate) for the long...

ATS 2017: New COPD action plan outlines strategies for improved care

(Michigan Medicine - University of Michigan) A Michigan Medicine researcher is a part of the National Institutes of Health's National Heart, Lung and Blood Institute group that recently created a new ...

FDA issues Complete Response Letter for Sunovion’s New Drug Application to treat COPD patients

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the New Drug Application for SUN-101/eFlow (glycopyrrolate) for the...

ME Association Petition: The NICE guideline for CFS/ME is not fit for purpose… | 10 July 2017

The ME Association has today launched a national petition that aims to demonstrate to NICE (National Institute for Health and Care Excellence) that people with CFS/ME are not happy with...

Drugs and Medications [268 Associated Drugs and Medications listed on BioPortfolio]

Spiriva [Physicians Total Care, Inc.]

These highlights do not include all the information needed to use SPIRIVA HandiHaler safely and effectively. See full prescribing information for SPIRIVA HandiHaler. SPIRIVA HandiHaler (tiotropium bro...

Spiriva [Boehringer Ingelheim Pharmaceuticals Inc.]

These highlights do not include all the information needed to use SPIRIVA HandiHaler safely and effectively. See full prescribing information for SPIRIVA HandiHaler. SPIRIVA HandiHaler (tiotropium bro...

Isoxsuprine hydrochloride [Bi-Coastal Pharmaceutical Corporation]

Isoxsuprine Hydrochloride Tablets, USP

Monk [National Towelette Company ]

Image of Label

Instant hand sanitizer foam [National Distribution & Contracting, Inc.]

Drug Facts

PubMed Articles [4373 Associated PubMed Articles listed on BioPortfolio]

Angiotensin Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography: The MESA Lung Study.

Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death in the United States. Emphysema on computed tomography (CT) is associated with increased morbidity and mortality in pat...

Quantifying the 'Lung at Risk' in COPD: Does Emphysema Beget Emphysema?

Measuring the Prevalence of Diagnosed Chronic Obstructive Pulmonary Disease in the United States Using Data From the 2012-2014 National Health Interview Survey.

This study, measuring the prevalence of chronic obstructive pulmonary disease (COPD), examined (1) whether a single survey question asking explicitly about diagnosed COPD is sufficient to identify US ...

Protective effect of Galectin-9 in murine model of lung emphysema: Involvement of neutrophil migration and MMP-9 production.

Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow obstruction and pulmonary emphysema. Persistent inflammation and remodeling of the lungs and airways result in red...

Matrix Metalloproteinase-28 Is a Key Contributor to Emphysema Pathogenesis.

Chronic obstructive pulmonary disease (COPD) comprises chronic bronchitis and emphysema, and is a leading cause of morbidity and mortality. Because tissue destruction is the prominent characteristic o...

Clinical Trials [3373 Associated Clinical Trials listed on BioPortfolio]

Assessment of Emphysema Using 1.5T MRI With UTE Pulse Sequences

Emphysema is a major pathological feature of Chronic Obstructive Pulmonary Disease (COPD). Non-invasive assessment of emphysema is a crucial issue for the phenotype and follow-up of COPD p...

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (>15 pack...

Biomarkers and Genetic Factors Related to Emphysema

Emphysema, a common type of chronic obstructive pulmonary disease (COPD), is a long-term lung disease that is usually caused by cigarette smoking. This study will examine both current smok...

Bronchoscopic EmphysemA Treatment in THE NetherLands

Rationale: New bronchoscopic treatments for emphysema have shown promise in clinical trials, improving lung function, exercise capacity and possibly survival and are now being adopted by a...

TESRA: (Treatment of Emphysema With a Gamma-Selective Retinoid Agonist)

This 2 arm study will investigate the efficacy, safety and tolerability of RAR Gamma versus placebo in ex-smokers with moderate or severe emphysema treated with optimal COPD therapy. Follo...

Companies [2178 Associated Companies listed on BioPortfolio]

National Emphysema/COPD Association

COPD Foundation

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the U.S. and the only chronic disease growing in mortality. It affects approximately 24 millio...

Theron Pharmaceuticals, Inc.

Headquartered in Sunnyvale, California, Theron Pharmaceuticals is committed to developing improved treatments for COPD and asthma. COPD is a slowly developing progressive small ai...

Hunter Immunology Limited

Our lead product is a vaccine currently called HI-164OV. It works by controlling bacterial colonisation of airways damaged by inhaled toxins. It has been developed to treat patients with Chronic O...

Uptake Medical Corp.

Uptake Medical(TM) Corp. is a developer of medical technologies for the treatment of lung diseases including emphysema. The core technology is a simple, minimally invasive, non-implant interventional ...

More Information about "National Emphysema/COPD Association" on BioPortfolio

We have published hundreds of National Emphysema/COPD Association news stories on BioPortfolio along with dozens of National Emphysema/COPD Association Clinical Trials and PubMed Articles about National Emphysema/COPD Association for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of National Emphysema/COPD Association Companies in our database. You can also find out about relevant National Emphysema/COPD Association Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record